Rezultati pretraživanja
  1. I try to keep Twitter non-personal, but had to share: we were matched to adopt 👶🏼 just after , but it failed. We were crushed. Now... hubs & I are in AZ waiting to take custody of our new 👶🏼 baby girl! 😳 She’s beautiful and perfect. 🙏🏻 – mjesto: Fairmont Scottsdale Princess

    Prikaži ovu nit
  2. Updated risk stratification model for SMM incorporating revised IMWG diagnostic criteria - San Miguel et al. 8000 2014 removal of SMM Pts at highest [ultra] risk of progression requires reassessment of current risk stratification models T1

  3. prije 18 sati

    It was nice to speak with my mentor at about our work (published in ) investigating response and survival outcomes in pts with advanced UC treated with checkpoint inhibitors

  4. At now, 's Caroline Schenkel discusses the study presented at which showed the Use of Broader Criteria for Enrollment Would **Double** Number of Eligible Patients w . 🔗

    Prikaži ovu nit
  5. The next story we're opening up for is a look into the most-discussed plenary session of : How a hackathon team linked expansion with reduction in racial disparities in time to cancer treatment —

  6. 3. velj

    Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis - et al. Abstract LBA108

  7. 3. velj

    Los doctores Jack West, Charu Aggarwal y Benjamin Levy se reunieron recientemente para revisar los principales puntos de discusión sobre de . En este video, analizan el en etapa 4 y los nuevos objetivos (targets), específicamente MET

    Prikaži ovu nit
  8. 2. velj
    Odgovor korisniku/ci

    Plenary re medicaid expansion used to show policy benefits (indirectly helps patients). FDA expansion of palbociclib for male breast Ca often cited by advocates. But companies $$ benefit is exponential (e.g. Roche's $1.9b acquisition of flatiron)

  9. 31. sij

    A retrospective analysis of clinical outcomes among patients with infiltrative hepatocellular carcinoma (iHCC): A single institution study - Hannan et al. 37, 2019 (suppl; Abstr e15667)

    Prikaži ovu nit
  10. 31. sij

    Oncology precision medicine for hepatobiliary and pancreatic cancer: an institutional review - Bellini et al. Abstr e14626

    Prikaži ovu nit
  11. 31. sij

    Hopefully the final results of the Durvalumab / Galunisertib trial (presented at ) will be published.

    Prikaži ovu nit
  12. 24. sij

    I hereby nominate for keynote speaker at ALL conferences. Between his remarkable, historically contextualized discussion at plenary and his forward-thinking examination of precision oncology care delivery at he is a nearly peerless orator in our field!

    Prikaži ovu nit
  13. 26. pro 2019.

    have the highest suicide rate of any profession, driven by the unique emotional challenges they face.

  14. 13. pro 2019.

    Until I became Chair of Annual Mtg Ed Comm, I didn’t realize how much weight ppl planning confs give to evals. I’ve read every single comment from session evals & they *directly* impacted my thoughts re . So attendees, do those evals. Be heard.

  15. 7. pro 2019.

    Thank you to for capturing this moment of & I crafting our first tweet about @ - an idea which no doubt was inspired by others like and more!

  16. 7. pro 2019.

    At , a patient, walked the posters with , a scientist. Corrie explained the hypotheses, experiments, & results. Christine talked about life with MBC, how different drugs affect her quality of life, what she is looking for in a treatment, 1/

    Prikaži ovu nit
  17. 19. stu 2019.

    New is out w of who deciphers and discusses advances. Amazing clinician, researcher, mentor, & educator took time last to speak w me. Find us on & other outlets.

  18. Prior important presentation ( + + vs. ) now in : unless visceral crisis, should always be given before CT in HR+ HER2- metastatic patients

  19. 28. lis 2019.

    This is just fascinating! A new era for the treatment of KRAS mutant lung cancer. After AMG510 preliminary clinical activity on KRAS G12C presented this year at , now MRTX849. The key was to tackled mutant KRAS in inactive GDP-bound state. And more to come!

  20. 30. ruj 2019.

    Live Tweet from the podium of YO brunch: Numbers from shows Oncologist engagement way up in Twitter, but we can not neglect our advocates. It is our duty to help amplify their voice!! . Thank you

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.